Most Recent
Gilbert + Tobin co-founder Danny Gilbert will step down from his role as managing partner of the law firm, saying it was time to open up the leadership to the next generation.
A Melbourne law firm has lost its bid to delay payment of a $184,000 judgment to a former junior lawyer who earned hundreds of thousands of dollars per year under a lucrative pay structure.
A judge has ordered that $1.27 million be set aside to cover the costs of the law firm administering the settlement in the class action over the federal government's Robodebt scheme, cutting about $1 million from the figure sought.
The Shop, Distributive and Allied Employees Association has flagged its intent to bring further cases against various McDonald’s franchisees, alongside eleven claims it has brought to date over alleged failures to give workers paid 10-minute breaks.
The High Court has agreed to weigh in on whether an Australian court's recognition of a $375 million international arbitration award against the kingdom of Spain violated the sovereign immunity doctrine.
In a victory for Victorian independent candidate Zoe Daniel, the state's Supreme Court has found that promotional signs displayed on lawns did not fall foul of a local council ban on unauthorised displays.
The former head of money markets at the Australian and New Zealand Banking Group has sued his former employer claiming he was sacked for making complaints about sexual harassment by senior managers at the bank and false reporting to the prudential regulator.
A Federal Court judgment has laid out when a responsible entity of a managed investment scheme will be indemnified for its operating costs and when it can recoup legal costs in defending lawsuits brought over trust property.
A judge has questioned whether the lead applicant in a class action over sleep apnea machines with alleged safety defects was “appropriately resourced” to run the case against health tech giant Philips.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.